FP/FORM Versus FP/SAL Within Clinical Practice: An Updated Budget Impact Analysis in Asthma
Conclusion
The use of FP/FORM as an alternative to FP/SAL can result in cost savings for the NHS when assessing drug, administration, monitoring and adverse events costs. The inclusion of data released since the launch of FP/FORM within the budget impact analysis demonstrates that the potential cost savings to the NHS that were previously published are being translated to clinical practice.
Funding
Mundipharma, UK.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Advair | Advair Diskus | Asthma | Clinical Trials | Drugs & Pharmacology | Flonase | Flovent | Health | UK Health